Treatment with High Dose [¹¹¹In-DTPA-D-PHE¹]-Octreotide in Patients with Neuroendocrine Tumors: Evaluation of Therapeutic and Toxic Effects

Author： Janson Eva Tiensuu Eriksson Barbro Öberg Kjell Skogseid Britt Öhrvall Ulf Nilsson Sten Westlin Jan-Erik

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.38, Iss.3, 1999-05, pp. : 373-377

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biodistribution data from 100 patients i.v. injected with 111 in-DTPA-D-Phe 1 -Octreotide

By Forssell-Aronsson Eva Bernhardt Peter Nilsson Ola Tisell Lars-Erik Wängberg Bo Ahlman Håkan

Acta Oncologica, Vol. 43, Iss. 5, 2004-07 ,pp. : 436-442

Informa Healthcare

Access to resources Recommend Favorite

Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

Cancer Medicine, Vol. 4, Iss. 6, 2015-06 ,pp. : 864-870

John Wiley & Sons Inc

Access to resources Recommend Favorite

New Treatment Options for Patients with Advanced Neuroendocrine Tumors

By Chan Jennifer

Current Treatment Options in Oncology, Vol. 12, Iss. 2, 2011-06 ,pp. : 136-148

Springer Publishing Company

Access to resources Recommend Favorite

Therapeutic Challenges in Neuroendocrine Tumors

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 17, Iss. 7, 2017-06 ,pp. : 902-919

Bentham Science Publishers

Access to resources Recommend Favorite

A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma

By Sulkowski U. Buchler M. Pederzoli P. Arnold R. Dinse P. Kay A. Haus U. Beger H.G.

European Journal of Cancer, Vol. 35, Iss. 13, 1999-12 ,pp. : 1805-1808

Elsevier

Access to resources Recommend Favorite